Ligand Pharma Files 8-K on Financial Results and Operations

TL;DR

Ligand Pharma just dropped an 8-K on their financial results today.

AI Summary

Ligand Pharmaceuticals Incorporated filed an 8-K on February 27, 2024, to report its Results of Operations and Financial Condition, along with Financial Statements and Exhibits. This routine filing, dated for the earliest event on February 27, 2024, provides an update on the company's financial performance. The document was filed from its principal executive offices at 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121.

Why It Matters

This 8-K provides investors with crucial, timely updates on Ligand Pharmaceuticals' financial performance and operational status, which can influence investment decisions and market perception.

Risk Assessment

Risk Level: low — This is a routine disclosure of financial results, which is standard for public companies and does not inherently indicate elevated risk.

Key Players & Entities

• LIGAND PHARMACEUTICALS INCORPORATED (company) — Registrant
• UNITED STATES SECURITIES AND EXCHANGE COMMISSION (company) — Regulator
• Delaware (state) — State of Incorporation
• San Diego, CA (location) — Business Address City/State
• February 27, 2024 (date) — Date of Report

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market

Filing Documents

• lgnd-20240227.htm (8-K) — 25KB
• q42023earningsrelease_ex991.htm (EX-99.1) — 236KB
• newligandlogoa.jpg (GRAPHIC) — 11KB
• 0000886163-24-000005.txt ( ) — 424KB
• lgnd-20240227.xsd (EX-101.SCH) — 2KB
• lgnd-20240227_lab.xml (EX-101.LAB) — 24KB
• lgnd-20240227_pre.xml (EX-101.PRE) — 12KB
• lgnd-20240227_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On February 27, 2024, Ligand Pharmaceuticals Incorporated (the "Company") issued a press release announcing its financial results for the three and twelve months ended December 31, 2023. A copy of this press release is furnished herewith as Exhibit 99.1 to this report. In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release dated February 27, 2024.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LIGAND PHARMACEUTICALS INCORPORATED Date: February 27, 2024 By: /s/ Andrew Reardon Name: Andrew Reardon Title: Chief Legal Officer and Secretary

View Full Filing

View this 8-K filing on SEC EDGAR